

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW.

First day of trading in Carasent AB (publ) on Nasdaq Stockholm

GOTHENBURG, 9 December 2024

As previously announced, on 5 December 2024, Carasent AB (publ) (the "Company") completed a cross-border merger with Carasent ASA to effect a relisting on Nasdaq Stockholm. Upon completion of the merger, all Carasent ASA shareholders had their shares in Carasent ASA exchanged one-for-one with shares in Carasent AB (publ), and Carasent ASA was delisted from Oslo Børs. Today, 9 December 2024, is the first day of trading in the shares of Carasent AB (publ) on Nasdaq Stockholm.

In connection with the listing on Nasdaq Stockholm certain board members and members of the management team (PDMRs), and persons closely associated with such persons, will report that they, as a result of the merger and as a part of the listing process, have received shares in the Company.

For further information, please contact

Daniel Öhman, CEO

Tel: +46 70-855 37 07, e-mail: daniel.ohman@carasent.com

Svein Martin Bjørnstad, CFO

Tel: +47 979 69 493, e-mail: svein.martin.bjornstad@carasent.com

The information was submitted for publication, through the agency of the contact persons set out above, on 9 december 2024 at 08:00 CET.

Carasent AB (publ) (Nasdaq Stockholm: CARA) delivers cloud based EHR solutions, with Webdoc as the leading platform, and a broad ecosystem of platform services, including solutions for patient communication and business intelligence. The ecosystem of solutions makes Carasent a one-stop shop for clinics and can cover all needs. Carasent believes in innovation that offers a new kind of accessibility and availability for patients and practices. The growing product portfolio comprises market-leading software solutions developed closely with customers and the respective target market.

IMPORTANT INFORMATION

The publication, release or distribution of this press release may be restricted in certain jurisdictions. Recipients of this press release in the jurisdictions in which this press release has been published, released or distributed should inform themselves about and observe such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Carasent in any jurisdiction.

This press release does not identify or attempt to identify any risks (direct or indirect) that may be associated with an investment in securities of Carasent. The information contained in this press release is published for background purposes only and does not purport to be complete.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended. The information contained in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction where such announcement, publication or distribution of this information would be contrary to applicable laws and regulations.

This press release is not a prospectus as defined in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Carasent has not authorized any offer of securities to the public in any member state of the European Economic Area ("EEA").

This press release contains certain forward-looking statements that reflect the Company's current views with respect to future events and financial and operational performance. Words such as "intends", "expects", "anticipates", "may", "plans", "believes", "estimates" and other expressions that are indicative or predictive of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By its nature, forward-looking information involves known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking statements are not guarantees of future performance or development and actual results may differ materially from those expressed in the forward-looking statements.